IP Receptor Activators

Prostaglandin I2 sodium, also known as prostacyclin sodium, is the sodium salt form of prostacyclin (PGI2). PGI2 is a member of the prostaglandin family, molecules derived from fatty acids that play roles in various physiological processes. Prostaglandin I2 sodium primarily activates the IP receptor, leading to a series of intracellular events. Activation of the IP receptor by PGI2 induces vasodilation and inhibits platelet aggregation, among other cellular responses.

Carbacyclin (Carbocyclic PGI2) with CAS 69552-46-1 is a synthetic analog of prostacyclin (PGI2). It retains the core structure of PGI2 but possesses a modified carbocyclic ring, differentiating it from the natural compound. Carbacyclin acts as an activator of the IP receptor, eliciting cellular responses similar to those triggered by PGI2. Specifically, upon binding to the IP receptor, it prompts vasodilation and inhibits platelet aggregation, among other physiological effects.

BMY 45778 functions as a selective modulator of IP receptors, exhibiting unique binding characteristics that enhance receptor activation. Its molecular interactions involve specific hydrogen bonding and hydrophobic contacts, which stabilize the receptor-ligand complex. The compound demonstrates a rapid onset of action, with a distinct kinetic profile that allows for fine-tuning of downstream signaling pathways. Additionally, its structural features facilitate selective receptor engagement, influencing cellular responses in a nuanced manner.

A synthetic prostacyclin analog that directly activates the IP receptor, mimicking the vasodilatory and antiplatelet effects of natural prostacyclin by elevating cAMP levels within cells.

NS-304 (CAS 475086-01-2) is a selective and direct agonist of the IP receptor. Upon binding, it activates the IP receptor, leading to various cellular responses. Its activation of the IP receptor can induce vasodilation and modulate other physiological processes associated with prostacyclin signaling. NS-304's structure and function allow it to mimic the actions of prostacyclin, making it an effective tool in studying IP receptor-mediated pathways.

Taprostene (CAS 108945-35-3) is a synthetic analog of prostacyclin. As an activator of the IP receptor, it binds and induces various cellular responses akin to natural prostacyclin. Specifically, taprostene's interaction with the IP receptor facilitates vasodilation and influences other physiological effects related to prostacyclin signaling. Its molecular design enables it to effectively simulate the actions of prostacyclin in IP receptor-mediated activities.

A prostacyclin analog that specifically activates the IP receptor, leading to increased cAMP production, which in turn facilitates vasodilation and inhibits platelet aggregation.

A synthetic analog of prostacyclin that activates the IP receptor, effectively increasing cAMP levels to elicit vasodilatory and antiplatelet aggregating responses.

Though primarily targeting the FP receptor for glaucoma management, it also exhibits some activity at IP receptors, activating them to a lesser extent, which may contribute to vasodilation through increased cAMP.